Triple Negative Breast Cancer, TNBC, a highly aggressive and metastatic type of breast cancer, is characterized by loss of expression of the estrogen receptor ( ER), progesterone receptor ( PR), and a lack of overexpression of the human epidermal growth factor receptor 2 ( HER2). It is a heterogeneous group of tumors with diverse histology, molecular uniqueness and response to treatment. Unfortunately, TNBC patients do not benefit from current anti-HER2 or hormone positive targeted breast cancer treatments; consequently, these patients rely primarily on chemotherapy. However, the 5-year survival rate for woman with metastatic TNBC is less than 30%. As a result of ineffective treatments, TNBC tumors often progress to metastatic lesions in the brain and lung. Brain metastases of invasive breast cancer are associated with 1 and 2 year survival rate of 20% and <2% respectively. Because the only current systemic treatment for TNBC is chemotherapy, alternative targeted therapies are urgently needed to improve the prognosis for TNBC patients. This review is focused on opportunities for developing new approaches for filling the current void in an effective treatment for TNBC patients.
References
[1]
Department of Health and Human Services, Center for Disease Control and Prevention. United States Cancer Statistics (USCS), 1999–2008 “Incidence and Mortality” web-based report; Centers for Disease Control and Prevention: Atlanta, GA, USA.
[2]
Fornier, M.; Fumoleau, P. The paradox of triple negative breast cancer: Novel approaches to treatment. Breast J. 2012, 18, 41–51, doi:10.1111/j.1524-4741.2011.01175.x.
[3]
Rakha, E.A.; Reis-Filho, J.S.; Ellis, I.O. Basal-like breast cancer: A critical review. J. Clin. Oncol. 2008, 26, 2568–2581, doi:10.1200/JCO.2007.13.1748.
S？rlie, T.; Perou, C.M.; Tibshirani, R. Aas, T.; Geisler, S.; Johnsen, H.; Hastie, T.; Eisen, M.B.; van de Rijn, M.; Jeffrey, S.S.; et al. Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications. Proc. Natl. Acad. Sci. USA 2001, 98, 10869–10874, doi:10.1073/pnas.191367098.
[6]
Sorlie, T.; Tibshirani, R.; Parker, J.; Hastie, T.; Marron, J.S.; Nobel, A.; Deng, S.; Johnsen, H.; Pesich, R.; Geisler, S.; et al. Repeated observation of breast tumor subtypes in independent gene expression data sets. Proc. Natl. Acad. Sci. USA 2003, 100, 8418–8423, doi:10.1073/pnas.0932692100.
[7]
Rakha, E.A.; El-Sayed, M.E.; Green, A.R.; Lee, A.H.; Robertson, J.F.; Ellis, I.O. Prognostic markers in triple-negative breast cancer. Cancer 2007, 109, 25–32.
[8]
Carey, L.A.; Perou, C.M.; Livasy, C.A.; Dressler, L.G.; Cowan, D.; Conway, K.; Karaca, G.; Troester, M.A.; Tse, C.K.; Edmiston, S.; et al. Race, breast cancer subtypes, and survival in the carolina breast cancer study. JAMA 2006, 295, 2492–2502, doi:10.1001/jama.295.21.2492.
[9]
Thike, A.A.; Cheok, P.Y.; Jara-Lazaro, A.R.; Tan, B.; Tan, P.; Tan, P.H. Triple-negative breast cancer: Clinicopathological characteristics and relationship with basal-like breast cancer. Mod. Pathol. 2010, 23, 123–133.
[10]
Banerjee, S.; Reis-Filho, J.S.; Ashley, S.; Steele, D.; Ashworth, A.; Lakhani, S.R.; Smith, I.E. Basal-Like breast carcinomas: Clinical outcome and response to chemotherapy. J. Clin. Pathol. 2006, 59, 729–735.
[11]
Jumppanen, M.; Gruvberger-Saal, S.; Kauraniemi, P.; Tanner, M.; Bendahl, P.O.; Lundin, M.; Krogh, M.; Kataja, P.; Borg, A.; Ferno, M.; et al. Basal-like phenotype is not associated with patient survival in estrogen-receptor-negative breast cancers. Breast Cancer Res. 2007, 9, R16.
[12]
Shakya, R.; Szabolcs, M.; McCarthy, E.; Ospina, E.; Basso, K.; Nandula, S.; Murty, V.; Baer, R.; Ludwig, T. The basal-like mammary carcinomas induced by Brca1 Or Bard1 inactivation implicate the BRCA1/BARD1 heterodimer in tumor suppression. Proc. Natl. Acad. Sci. USA 2008, 105, 7040–7045.
[13]
Langerod, A.; Zhao, H.; Borgan, O.; Nesland, J.M.; Bukholm, I.R.; Ikdahl, T.; Karesen, R.; Borresen-Dale, A.L.; Jeffrey, S.S. TP53 mutation status and gene expression profiles are powerful prognostic markers of breast cancer. Breast Cancer Res. 2007, 9, R30, doi:10.1186/bcr1675.
[14]
Subhawong, A.P.; Subhawong, T.; Nassar, H.; Kouprina, N.; Begum, S.; Vang, R.; Westra, W.H.; Argani, P. Most basal-like breast carcinomas demonstrate the same Rb？/p16+ immunophenotype as the HPV-related poorly differentiated squamous cell carcinomas which they resemble morphologically. Am. J. Surg. Pathol. 2009, 33, 163–175, doi:10.1097/PAS.0b013e31817f9790.
[15]
Gauthier, M.L.; Berman, H.K.; Miller, C.; Kozakeiwicz, K.; Chew, K.; Moore, D.; Rabban, J.; Chen, Y.Y.; Kerlikowske, K.; Tlsty, T.D. Abrogated response to cellular stress identifies DCIS associated with subsequent tumor events and defines basal-like breast tumors. Cancer. Cell 2007, 12, 479–491, doi:10.1016/j.ccr.2007.10.017.
[16]
Dent, R.; Trudeau, M.; Pritchard, K.I.; Hanna, W.M.; Kahn, H.K.; Sawka, C.A.; Lickley, L.A.; Rawlinson, E.; Sun, P.; Narod, S.A. Triple-negative breast cancer: Clinical features and patterns of recurrence. Clin. Cancer Res. 2007, 13, 4429–4434.
Liu, T.; Yacoub, R.; Taliaferro-Smith, L.D. Sun, S.Y.; Graham, T.R.; Dolan, R.; Lobo, C.; Tighiouart, M.; Yang, L.; Adams, A.; et al. Combinatorial effects of lapatinib and rapamycin in triple-negative breast cancer cells. Mol. Cancer Ther. 2011, 10, 1460–1469, doi:10.1158/1535-7163.MCT-10-0925.
[19]
Banerji, S.; Cibulskis, K.; Rangel-Escareno, C.; Brown, K.K.; Carter, S.L.; Frederick, A.M.; Lawrence, M.S.; Sivachenko, A.Y.; Sougnez, C.; Zou, L.; et al. Sequence analysis of mutations and translocations across breast cancer subtypes. Nature 2012, 486, 405–409, doi:10.1038/nature11154.
Perou, C.M.; Sorlie, T.; Eisen, M.B.; van de Rijn, M.; Jeffrey, S.S.; Rees, C.A.; Pollack, J.R.; Ross, D.T.; Johnsen, H.; Akslen, L.A.; et al. Molecular portraits of human breast tumours. Nature 2000, 406, 747–752.
[22]
Rouzier, R.; Perou, C.M.; Symmans, W.F.; Ibrahim, N.; Cristofanilli, M.; Anderson, K.; Hess, K.R.; Stec, J.; Ayers, M.; Wagner, P.; et al. Breast cancer molecular subtypes respond differently to preoperative chemotherapy. Clin. Cancer Res. 2005, 11, 5678–5685, doi:10.1158/1078-0432.CCR-04-2421.
[23]
Calza, S.; Hall, P.; Auer, G.; Bjohle, J.; Klaar, S.; Kronenwett, U.; Liu, E.T.; Miller, L.; Ploner, A.; Smeds, J.; et al. Intrinsic molecular signature of breast cancer in a population-based cohort of 412 patients. Breast Cancer Res. 2006, 8, R34.
[24]
Bertucci, F.; Finetti, P.; Cervera, N.; Esterni, B.; Hermitte, F.; Viens, P.; Birnbaum, D. How basal are triple-negative breast cancers? Int. J. Cancer 2008, 123, 236–240, doi:10.1002/ijc.23518.
[25]
Tischkowitz, M.; Brunet, J.S.; Begin, L.R.; Huntsman, D.G.; Cheang, M.C.; Akslen, L.A.; Nielsen, T.O.; Foulkes, W.D. Use of immunohistochemical markers can refine prognosis in triple negative breast cancer. BMC Cancer 2007, 7, 134, doi:10.1186/1471-2407-7-134.
[26]
Bidard, F.C.; Conforti, R.; Boulet, T.; Michiels, S.; Delaloge, S.; Andre, F. Does triple-negative phenotype accurately identify basal-like tumour? An immunohistochemical analysis based on 143 “triple-negative” breast cancers. Ann. Oncol. 2007, 18, 1285–1286, doi:10.1093/annonc/mdm360.
[27]
Tan, D.S.; Marchio, C.; Jones, R.L.; Savage, K.; Smith, I.E.; Dowsett, M.; Reis-Filho, J.S. Triple negative breast cancer: Molecular profiling and prognostic impact in adjuvant anthracycline-treated patients. Breast Cancer Res. Treat. 2008, 111, 27–44, doi:10.1007/s10549-007-9756-8.
Lin, N.U.; Vanderplas, A.; Hughes, M.E.; Theriault, R.L.; Edge, S.B.; Wong, Y.N.; Blayney, D.W.; Niland, J.C.; Winer, E.P.; Weeks, J.C. Clinicopathologic features, patterns of recurrence, and survival among women with triple-negative breast cancer in the national comprehensive cancer network. Cancer 2012, 118, 5463–5472, doi:10.1002/cncr.27581.
[30]
Oakman, C.; Viale, G.; di Leo, A. Management of triple negative breast cancer. Breast 2010, 19, 312–321, doi:10.1016/j.breast.2010.03.026.
[31]
Badve, S.; Dabbs, D.J.; Schnitt, S.J.; Baehner, F.L.; Decker, T.; Eusebi, V.; Fox, S.B.; Ichihara, S.; Jacquemier, J.; Lakhani, S.R.; et al. Basal-like and triple-negative breast cancers: A critical review with an emphasis on the implications for pathologists and oncologists. Mod. Pathol. 2011, 24, 157–167.
[32]
Hudis, C.A.; Gianni, L. Triple-negative breast cancer: An unmet medical need. Oncologist 2011, 16, 1–11, doi:10.1634/theoncologist.2011-S1-01.
[33]
Gril, B.; Palmieri, D.; Bronder, J.L.; Herring, J.M.; Vega-Valle, E.; Feigenbaum, L.; Liewehr, D.J.; Steinberg, S.M.; Merino, M.J.; Rubin, S.D.; et al. Effect of lapatinib on the outgrowth of metastatic breast cancer cells to the brain. J. Natl. Cancer Inst. 2008, 100, 1092–1103, doi:10.1093/jnci/djn216.
[34]
Chitnis, M.M.; Yuen, J.S.P.; Protheroe, A.S.; Pollack, M.; Macaulay, V.M. The type 1 insulin-like growth factor receptor pathway. Mol. Path. 2008, 14, 6364–6370.
[35]
Jones, S.E.; Savin, M.A.; Holmes, F.A.; O’Shaughnessy, J.A. Phase III trial comparing doxorubicin plus cyclophosphamide with docetaxel plus cyclophosphamide as adjuvant therapy for operable breast cancer. J. Clin. Oncol. 2007, 24, 5381–5387.
[36]
Lehmann, B.D.; Bauer, J.A.; Chen, X.; Sanders, M.E.; Chakravarthy, A.B.; Shyr, Y.; Pietenpol, J.A. Identification of human triple-negative breast cancer subtypes and preclinical models for selection of targeted therapies. J. Clin. Invest. 2011, 121, 2750–2767, doi:10.1172/JCI45014.
[37]
Liedtke, C.; Mazouni, C.; Hess, K.R.; Andre, F.; Tordai, A.; Mejia, J.A.; Symmans, W.F.; Gonzalez-Angulo, A.M.; Hennessy, B.; Green, M.; et al. Response to neoadjuvant therapy and long-term survival in patients with triple-negative breast cancer. J. Clin. Oncol. 2008, 26, 1275–1281.
[38]
Bos, P.D.; Zhang, X.H.; Nadal, C.; Shu, W.; Gomis, R.R.; Nguyen, D.X.; Minn, A.J.; van de Vijver, M.J.; Gerald, W.L.; Foekens, J.A.; et al. Genes that mediate breast cancer metastasis to the brain. Nature 2009, 459, 1005–1009.
[39]
El Guerrab, A.; Zegrour, R.; Nemlin, C.C.; Vigier, F.; Cayre, A.; Penault-Llorca, F.; Rossignol, F.; Bignon, Y.J. Differential impact of egfr-targeted therapies on hypoxia responses: Implications for treatment sensitivity in triple-negative metastatic breast cancer. PLoS One 2011, 6, e25080.
[40]
Fitzgerald, D.P.; Palmieri, D.; Hua, E.; Hargrave, E.; Herring, J.M.; Qian, Y.; Vega-Valle, E.; Weil, R.J.; Stark, A.M.; Vortmeyer, A.O.; et al. Reactive glia are recruited by highly proliferative brain metastases of breast cancer and promote tumor cell colonization. Clin. Exp. Metastasis 2008, 25, 799–810, doi:10.1007/s10585-008-9193-z.
[41]
Kassam, F.; Enright, K.; Dent, R.; Dranitsaris, G.; Myers, J.; Flynn, C.; Fralick, M.; Kumar, R.; Clemons, M. Survival outcomes for patients with metastatic triple-negative breast cancer: Implications for clinical practice and trial design. Clin. Breast Cancer 2009, 1, 29–33.
[42]
Lin, N.U.; Claus, E.; Sohl, J.; Razzak, A.R.; Arnaout, A.; Winer, E.P. Sites of distant recurrence and clinical outcomes in patients with metastatic triple-negative breast cancer: High incidence of central nervous system metastases. Cancer 2008, 113, 2638–2645.
Cancello, G.; Maisonneuve, P.; Rotmensz, N.; Viale, G.; Mastropasqua, M.G.; Pruneri, G.; Veronesi, P.; Torrisi, R.; Montagna, E.; Luini, A.; et al. Prognosis and adjuvant treatment effects in selected breast cancer subtypes of very young women (<35 years) with operable breast cancer. Ann. Oncol. 2010, 21, 1974–1981.
[45]
Klein, A.; Olendrowitz, C.; Schmutzler, R.; Hampl, J.; Schlag, P.M.; Maass, N.; Arnold, N.; Wessel, R.; Ramser, J.; Meindl, A.; et al. Identification of brain- and bone-specific breast cancer metastasis genes. Cancer Lett. 2009, 276, 212–220, doi:10.1016/j.canlet.2008.11.017.
[46]
Dufour, M.; Dormaond-Meuwly, A.; Demartines, N.; Dormond, O. Targeting the mammalian target of rapamycin (mtor) in cancer therapy: Lessons from past and future perspectives. Cancer 2011, 3, 2478–2500, doi:10.3390/cancers3022478.
[47]
Populo, H.; Lopes, J.M.; Soares, P. The mTOR signaling pathway in human cancer. Int. J. Mol. Sci. 2012, 13, 1886–1918, doi:10.3390/ijms13021886.
[48]
Paranjape, T.; Heneghan, H.; Lindner, R.; Keane, F.K.; Hoffman, A.; Hollestelle, A.; Dorairaj, J.; Geyda, K.; Pelletier, C.; Nallur, S.; et al. A 3'-untranslated region KRAS variant and triple-negative breast cancer: A case-control and genetic analysis. Lancet Oncol. 2011, 12, 377–386, doi:10.1016/S1470-2045(11)70044-4.
Ozes, O.N.; Akca, H.; Mayo, L.D.; Gustin, J.A.; Maehama, T.; Dixon, J.E.; Donner, D.B. A phosphatidylinositol 3-kinase/Akt/mTOR pathway mediates and PTEN antagonizes tumor necrosis factor inhibition of insulin signaling through insulin receptor substrate-1. Proc. Natl. Acad. Sci. USA 2001, 98, 4640–4645.
[56]
Tsutsui, S.; Ohno, S.; Murakami, S.; Hachitanda, Y.; Oda, S. Prognostic value of epidermal growth factor receptor (EGFR) and its relationship to the estrogen receptor status in 1029 patients with breast cancer. Breast Cancer Res. Treat. 2002, 71, 67–75, doi:10.1023/A:1013397232011.
[57]
Agrawal, A.; Gutteridge, E.; Gee, J.M.; Nicholson, R.I.; Robertson, J.F. Overview of tyrosine kinase inhibitors in clinical breast cancer. Endocr. Relat. Cancer 2005, 12, 135–144, doi:10.1677/erc.1.00897.
[58]
Inoue, S.; Patil, R.; Portilla-Arias, J.; Ding, H.; Konda, B.; Espinoza, A.; Mongayt, D.; Markman, J.L.; Elramsisy, A.; Phillips, H.W.; et al. Nanobiopolymer for direct targeting and inhibition of egfr expression in triple negative breast cancer. PLoS One 2012, 7, e31070.
[59]
Peddi, P.F.; Ellis, M.J.; Ma, C. Molecular basis of triple negative breast cancer and implications for therapy. Int. J. Breast Cancer 2012, 2012, 217185.
[60]
Irvin, W.J., Jr; Carey, L.A. What is triple-negative breast cancer? Eur. J. Cancer 2008, 44, 2799–2805, doi:10.1016/j.ejca.2008.09.034.
[61]
Dogu, G.G.; Ozkan, M.; Ozturk, F.; Dikilitas, M.; Er, O.; Ozturk, A. Triple-negative breast cancer: Immunohistochemical correlation with basaloid markers and prognostic value of survivin. Med. Oncol. 2010, 27, 34–39, doi:10.1007/s12032-009-9166-3.
[62]
Ueno, N.T.; Zhang, D. Targeting EGFR in triple negative breast cancer. J. Cancer 2011, 2, 324–328, doi:10.7150/jca.2.324.
[63]
Grunstein, M. Histone acetylation in chromatin structure and transcription. Nature 2012, 389, 349–352, doi:10.1038/38664.
[64]
Baserga, R.; Peruzzi, F.; Reiss, K. The IGF-1 receptor in cancer biology. Int. J. Cancer 2003, 107, 873–877, doi:10.1002/ijc.11487.
[65]
Sell, C.; Dumenil, G.; Deveaud, C.; Miura, M.; Coppola, D.; DeAngelis, T.; Rubin, R.; Efstratiadis, A.; Baserga, R. Effect of a null mutation of the insulin-like growth factor I receptor gene on growth and transformation of mouse embryo fibroblasts. Mol. Cell. Biol. 1994, 14, 3604–3612.
[66]
Lopez, T.; Hanahan, D. Elevated levels of IGF-1 receptor convey invasive and metastatic capability in a mouse model of pancreatic Islet tumorigenesis. Cancer Cell. 2002, 1, 339–353, doi:10.1016/S1535-6108(02)00055-7.
Plymate, S.R.; Haugk, K.; Coleman, I.; Woodke, L.; Vessella, R.; Nelson, P.; Montgomery, R.B.; Ludwig, D.L.; Wu, J.D. An antibody targeting the type I insulin-like growth factor receptor enhances the castration-induced response in androgen-dependent prostate cancer. Clin. Cancer Res. 2007, 13, 6429–6439, doi:10.1158/1078-0432.CCR-07-0648.
[69]
Natrajan, R.; Lambros, M.B.; Rodriguez-Pinilla, S.M.; Moreno-Bueno, G.; Tan, D.S.; Marchio, C.; Vatcheva, R.; Rayter, S.; Mahler-Araujo, B.; Fulford, L.G.; et al. Tiling path genomic profiling of grade 3 invasive ductal breast cancers. Clin. Cancer Res. 2009, 15, 2711–2722, doi:10.1158/1078-0432.CCR-08-1878.
[70]
Bergamaschi, A.; Kim, Y.H.; Wang, P.; Sorlie, T.; Hernandez-Boussard, T.; Lonning, P.E.; Tibshirani, R.; Borresen-Dale, A.L.; Pollack, J.R. Distinct patterns of DNA copy number alterationare associated with different clinicopathological features and gene-expression subtypes of breast cancer. Genes Chromosomes Cancer 2006, 45, 1033–1040, doi:10.1002/gcc.20366.
[71]
Cheang, M.C.; Voduc, D.; Bajdik, C.; Leung, S.; McKinney, S.; Chia, S.K.; Perou, C.M.; Nielsen, T.O. Basal-like breast cancer defined by five biomarkers has superior prognostic value than triple-negative phenotype. Clin. Cancer Res. 2008, 14, 1368–1376, doi:10.1158/1078-0432.CCR-07-1658.
[72]
Anderson, W.F.; Chatterjee, N.; Ershler, W.B.; Brawley, O.W. Estrogen receptor breast cancer phenotypes in the surveillance, epidemiology, and end results database. Breast Cancer Res. Treat. 2002, 76, 27–36, doi:10.1023/A:1020299707510.
[73]
Rakha, E.A.; El-Sayed, M.E.; Green, A.R.; Paish, E.C.; Powe, D.G.; Gee, J.; Nicholson, R.I.; Lee, A.H.; Robertson, J.F.; Ellis, I.O. Biologic and clinical characteristics of breast cancer with single hormone receptor positive phenotype. J. Clin. Oncol. 2007, 25, 4772–4778, doi:10.1200/JCO.2007.12.2747.
[74]
Prat, A.; Baselga, J. The role of hormonal therapy in the management of hormonal-receptor-positive breast cancer with co-expression of HER2. Nat. Clin. Pract. Oncol. 2008, 5, 531–542, doi:10.1038/ncponc1179.
[75]
Atchley, D.P.; Albarracin, C.T.; Lopez, A.; Valero, V.; Amos, C.I.; Gonzalez-Angulo, A.M.; Hortobagyi, G.N.; Arun, B.K. Clinical and pathologic characteristics of patients with BRCA-positive and BRCA-negative breast cancer. J. Clin. Oncol. 2008, 26, 4282–4288, doi:10.1200/JCO.2008.16.6231.
[76]
Foulkes, W.D.; Brunet, J.S.; Stefansson, I.M.; Straume, O.; Chappuis, P.O.; Begin, L.R.; Hamel, N.; Goffin, J.R.; Wong, N.; Trudel, M.; et al. The prognostic implication of the basal-like (Cyclin E high/p27 low/p53+/+glomeruloid-microvascular-proliferation) phenotype of BRCA1-related breast cancer. Cancer Res. 2004, 64, 830–835, doi:10.1158/0008-5472.CAN-03-2970.
[77]
Gonzalez-Angulo, A.M.; Hortobagyi, G.N. Is there an ideal way to combine trastuzumab with chemotherapy? J. Clin. Oncol. 2011, 29, 4474–4476, doi:10.1200/JCO.2011.38.3836.
[78]
Sirohi, B.; Arnedos, M.; Popat, S.; Ashley, S.; Nerurkar, A.; Walsh, G.; Johnston, S.; Smith, I.E. Platinum-based chemotherapy in triple-negative breast cancer. Ann. Oncol. 2008, 19, 1847–1852, doi:10.1093/annonc/mdn395.
[79]
Chalmers, A.J. The potential role and application of PARP inhibitors in cancer treatment. Breast Med. Bull. 2009, 89, 23–40, doi:10.1093/bmb/ldp005.
[80]
Guo, G.; Zhang, F.; Gao, R.; Delsite, R.; Feng, Z.; Powell, S. DNA repair and synthetic lethality. Int. J. Oral Sci. 2011, 3, 176–179, doi:10.4248/IJOS11064.
[81]
Au-Yong, I.T.; Evans, A.J.; Taneja, S.; Rakha, E.A.; Green, A.R.; Paish, C.; Ellis, I.O. Sonographic correlations with the new molecular classification of invasive breast cancer. Eur. Radiol. 2009, 19, 2342–2348, doi:10.1007/s00330-009-1418-2.
[82]
Fong, P.C.; Boss, D.S.; Yap, T.A.; Tutt, A.; Wu, P.; Mergui-Roelvink, M.; Mortimer, P.; Swaisland, H.; Lau, A.; O’Connor, M.J.; et al. Inhibition of Poly(ADP-ribose) polymerase in tumors from BRCA mutation carriers. N. Engl. J. Med. 2009, 361, 123–134, doi:10.1056/NEJMoa0900212.
[83]
Farmer, H.; McCabe, N.; Lord, C.J.; Tutt, A.N.; Johnson, D.A.; Richardson, T.B.; Santarosa, M.; Dillon, K.J.; Hickson, I.; Knights, C.; et al. Targeting the DNA repair defect in BRCA mutant cells as a therapeutic strategy. Nature 2005, 434, 917–921, doi:10.1038/nature03445.
[84]
Bryant, H.E.; Schultz, N.; Thomas, H.D.; Parker, K.M.; Flower, D.; Lopez, E.; Kyle, S.; Meuth, M.; Curtin, N.J.; Helleday, T. Specific killing of BRCA2-deficient tumours with inhibitors of poly(ADP-ribose) polymerase. Nature 2005, 434, 913–917, doi:10.1038/nature03443.
[85]
Finn, R.S.; Bengala, C.; Ibrahim, N.; Roche, H.; Sparano, J.; Strauss, L.; Fairchild, J.; Sy, O.; Goldstein, L.J. Dasatinib as a single agent in triple negative breast cancer: Results of an open-labeled phase 2 study. Clin. Cancer Res. 2011, 21, 6905–6913.
[86]
Gnoni, A.; Marech, I.; Silvestris, N.; Vacca, A.; Lorusso, V. Dasatinib: An anti-tumour agent via Src inhibition. Curr. Drug Targets 2011, 4, 563–578.
[87]
Tryfonopoulos, D.; Walsh, S.; Collins, D.M.; Flanagan, L.; Quinn, C.; Corkery, B.; McDermott, E.W.; Evoy, D.; Pierce, A.; O’Donovan, N.; et al. Src: A potential target for the treatment of triple-negative breast cancer. Ann. Oncol. 2011, 10, 2234–2240.
[88]
Chiosis, G.; Caldas-Lopes, E.; Solit, D. Heat shock protein-90 inhibitors: A chronicle from geldanamycin to today’s agents. Curr. Opin. Inv. Drugs 2006, 6, 534–541.
[89]
Caldas-lopes, E.; Cerchietti, L.; Ahn, J.; Clement, C.; Robles, A.; Rodina, A.I.; Rodina, A.; Moylick, K.; Taldone, T.; Gozman, A.; et al. Hsp90 inhibitor PU-H71, a multimodal inhibitor of malignancy, induces complete responses in triple-negative breast cancer models. Proc. Natl. Acad. Sci. USA 2009, 106, 8368–8373, doi:10.1073/pnas.0903392106.
[90]
Patel, H.J.; Modi, S.; Chiosis, G.; Taldone, T. Advances in the discovery and development of heat-shock protein 90 inhibitors for cancer treatment. Expert Opin. Drug Discov. 2011, 6, 559–587, doi:10.1517/17460441.2011.563296.
[91]
Modi, S.; Stopeck, A.; Linden, H.; Solit, D.; Chandarlapaty, S.; Rosen, N.; D’Andrea, G.; Dickler, M.; Moynahan, M.; Sugarman, S.; et al. HSP90 inhibition is effective in breast cancer: A phase II trial of tanespimycin (17-AAG) plus trastuzumab in patients with HER2-positive metastatic breast cancer progressing on trastuzumab. Clin. Cancer Res. 2011, 17, 5132–5139, doi:10.1158/1078-0432.CCR-11-0072.
[92]
Haluska, P.; Shaw, H.M.; Batzel, G.N.; Yin, D.; Molina, J.R.; Molife, L.R.; Yap, T.A.; Roberts, M.L.; Sharma, A.; Gualberto, A.; et al. Phase I dose escalation study of the anti insulin-like growth factor-I receptor monoclonal antibody CP-751,871 in patients with refractory solid tumors. Clin. Cancer Res. 2007, 13, 5834–5840, doi:10.1158/1078-0432.CCR-07-1118.
[93]
Ryan, C.J.; Harzstark, A.H.; Rosenberg, J.; Lin, A.; Claros, C.; Goldfine, I.D.; Kerner, J.F.; Small, E.J.; Youngren, J.F. A Pilot Dose-escalation study of the effects of nordihydroguareacetic acid on hormone and prostate specific antigen levels in patients with relapsed prostate cancer. BJU Int. 2008, 101, 436–439, doi:10.1111/j.1464-410X.2007.07330.x.
[94]
Rochester, M.A.; Riedemann, J.; Hellawell, G.O.; Brewster, S.F.; Macaulay, V.M. Silencing of the IGF1R gene enhances sensitivity to DNA-damaging agents in both PTEN wild-type and mutant human prostate cancer. Cancer Gene Ther. 2005, 12, 90–100, doi:10.1038/sj.cgt.7700775.
[95]
Yeh, A.H.; Bohula, E.A.; Macaulay, V.M. Human melanoma cells expressing V600E B-RAF are susceptible to IGF1R targeting by small interfering RNAs. Oncogene 2006, 25, 6574–6581, doi:10.1038/sj.onc.1209674.
[96]
Haluska, P.; Carboni, J.M.; TenEyck, C.; Attar, R.M.; Hou, X.; Yu, C.; Sagar, M.; Wong, T.W.; Gottardis, M.M.; Erlichman, C. HER receptor signaling confers resistance to the insulin-like growth factor-I receptor inhibitor, BMS-536924. Mol. Cancer Ther. 2008, 7, 2589–2598, doi:10.1158/1535-7163.MCT-08-0493.
[97]
Jerome, L.; Alami, N.; Belanger, S.; Page, V.; Yu, Q.; Paterson, J.; Shiry, L.; Pegram, M.; Leyland-Jones, B. Recombinant human insulin-like growth factor binding protein 3 inhibits growth of human epidermal growth factor receptor-2-overexpressing breast tumors and potentiates herceptin activity in vivo. Cancer Res. 2006, 66, 7245–7252, doi:10.1158/0008-5472.CAN-05-3555.
[98]
Lu, D.; Zhang, H.; Koo, H. Tonra, J.; Balderes, P.; Prewett, M.; Corcoran, E.; Mangalampalli, V.; Bassi, R.; Anselma, D.; et al. A fully human recombinant IgG-like bispecific antibody to both the epidermal growth factor receptor and the insulin-like growth factor receptor for enhanced antitumor activity. J. Biol. Chem. 2005, 280, 19665–19672, doi:10.1074/jbc.M500815200.
[99]
Oliveras-Ferraros, C.; Vazquez-Martin, A.; Lopez-Bonet, E.; Martin-Castillo, B.; del Barco, S.; Brunet, J.; Menendez, J.A. Growth and molecular interactions of the anti-EGFR antibody cetuximab and the DNA cross-linking agent cisplatin in gefitinib-resistant MDA-MB-468 cells: New prospects in the treatment of triple-negative/basal-like breast cancer. Int. J. Oncol. 2008, 33, 1165–1176.
[100]
Nowsheen, S.; Cooper, T.; Stanley, J.A.; Yang, E.S. Synthetic lethal interactions between EGFR and PARP inhibition in human triple negative breast cancer cells. PLoS One 2012, 7, e46614.
[101]
Lee, E.S.; Na, K.; Bae, Y.H. Doxorubicin loaded pH-sensitive polymeric micelles for reversal of resistant MCF-7 tumor. J. Contr. Release 2005, 103, 405–418, doi:10.1016/j.jconrel.2004.12.018.
[102]
Patel, N.R.; Rathi, A.; Mongayt, D.; Torchilin, V.P. Reversal of multidrug resistance by Co-delivery of tariquidar (XR9576) and paclitaxel using long-circulating liposomes. Int. J. Pharm. 2011, 416, 296–299, doi:10.1016/j.ijpharm.2011.05.082.
[103]
Li, B.; Xu, H.; Li, Z.; Yao, M.; Xie, M.; Shen, H.; Shen, S.; Wang, X.; Jin, Y. Bypassing multidrug resistance in human breast cancer cells with lipid/polymer particle assemblies. Int. J. Nanomed. 2012, 7, 187–197.
[104]
Lee, S.M.; Ahn, R.W.; Chen, F.; Fought, A.J.; O’Halloran, T.V.; Cryns, V.L.; Nguyen, S.T. Biological evaluation of pH-responsive polymer-caged nanobins for breast cancer therapy. ACS Nano 2010, 4, 4971–4978, doi:10.1021/nn100560p.
[105]
Ahn, R.W.; Chen, F.; Chen, H.; Stern, S.T.; Clogston, J.D.; Patri, A.K.; Raja, M.R.; Swindell, E.P.; Parimi, V.; Cryns, V.L.; et al. A novel nanoparticulate formulation of arsenic trioxide with enhanced therapeutic efficacy in a murine model of breast cancer. Clin. Cancer Res. 2010, 16, 3607–3617, doi:10.1158/1078-0432.CCR-10-0068.
[106]
Shao, W.; Paul, A.; Abbasi, S.; Chahal, P.S.; Mena, J.A.; Montes, J.; Kamen, A.; Prakesh, S. A novelpolyethyleneimine-coatedadeno-associated virus-like particle formulation for efficient siRNAdelivery in breast cancer therapy: Preparation and in vitro analysis. Int. J. Nanomed. 2012, 7, 1575–1586.
[107]
Hussein, Y.R.; Sood, A.K.; Bandyopadhyay, S.; Albashiti, B.; Semaan, A.; Nahleh, Z.; Roh, J.; Han, H.D.; Lopez-Berestein, G.; Ali-Fehmi, R. Clinical and biological relevance of enhancer of zeste homolog 2 in triple-negative breast cancer. Hum. Pathol. 2012, 43, 1638–1644, doi:10.1016/j.humpath.2011.12.004.
[108]
Tekedereli, I.; Alpay, S.N.; Tavares, C.D.; Cobanoglu, Z.E.; Kaoud, T.S.; Sahin, I.; Sood, A.K.; Lopez-Berestein, G.; Dalby, K.N.; Ozpolat, B. Targeted silencing of elongation factor 2 kinase suppresses growth and sensitizes tumors to doxorubicin in an orthotopic model of breast cancer. PLoS One 2012, 7, e41171, doi:10.1371/journal.pone.0041171.
[109]
Vander Heiden, M.G.; Cantley, L.C.; Thompson, C.B. Understanding the warburg effect: The metabolic requirements of cell proliferation. Science 2009, 324, 1029–1033, doi:10.1126/science.1160809.
[110]
Sabnis, N.; Lacko, A.G. Drug delivery via lipoprotein-based carriers: Answering the challenges in systemic therapeutics. Ther. Deliv. 2012, 3, 599–608, doi:10.4155/tde.12.41.
[111]
Lacko, A.G.; Nair, M.; Paranjape, S.; Mooberry, L.; McConathy, W.J. Trojan horse meets magic bullet to spawn a novel, highly effective drug delivery model. Chemotherapy 2006, 52, 171–173, doi:10.1159/000093268.
